Osteoporosis in the adult solid organ transplant population: underlying mechanisms and available treatment options.
Study Goal
The researchers aimed to evaluate the role of calcium supplementation in preventing and treating osteoporosis in solid organ transplant (SOT) patients.
Results Summary
Calcium and vitamin D supplementation is often necessary in SOT patients due to high vitamin D deficiency rates, but the abstract does not specify calcium's direct efficacy. Bisphosphonates are commonly used, though limited by renal dysfunction, while alternative agents like teriparatide and calcitonin showed minimal impact on fracture rates.
Population
Solid organ transplant recipients at elevated risk of osteoporosis.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
calcium and vitamin D supplementation | neutral | vitamin D deficiency | the SOT population | - | is often necessary | #1 |
Bisphosphonate therapy | neutral | prevention and treatment of osteoporosis | - | - | is most commonly used | #2 |
Bisphosphonate therapy | neutral | renal dysfunction | transplant recipients | - | can be limited | #3 |
Alternative agents such as teriparatide and calcitonin | no change | the rate of fractures | this population | no significant impact | have not been shown to provide a significant impact | #4 |
denosumab | neutral | - | - | - | may be a promising treatment option | #5 |
denosumab | neutral | - | renal transplant patients | - | is currently being studied | #6 |
Timely initiation of supplementation and treatment, and minimizing glucocorticoid exposure | neutral | osteoporosis | these patients | - | will aid in the prevention and proper management | #7 |
The prevention and treatment of osteoporosis is an increasingly important topic in the solid organ transplant (SOT) population. Compared to the general population, these patients are at an elevated risk of developing osteoporosis due to progressive disease, lifelong immunosuppressant therapy, and malnutrition. As patients live longer after transplant, chronic disease management is increasingly more important. Supplementation with calcium and vitamin D is often necessary in the SOT population due to a high incidence of vitamin D deficiency. Bisphosphonate therapy is most commonly used for prevention and treatment of osteoporosis, but therapy can be limited by renal dysfunction which is common in transplant recipients. Alternative agents such as teriparatide and calcitonin have not been shown to provide a significant impact on the rate of fractures in this population. Additionally, denosumab may be a promising treatment option due to its novel mechanism of action, and is currently being studied in renal transplant patients. Timely initiation of supplementation and treatment, and minimizing glucocorticoid exposure prior to and after transplantation will aid in the prevention and proper management of osteoporosis in these patients.